Una nuova linea guida multi-organizzativa presenta 26 raccomandazioni per il […]
Search Results for: Nuovi possibili trattamenti per il morbo di Alzheimer
Here's what we've found for you
Infezioni sessualmente trasmissibili: troppo pochi i test nella popolazione [Infettivologia]
Presentato alla Camera il Report “Infezioni Sessualmente Trasmesse: Barriere e soluzioni della diagnosi precoce”. Partendo da due sondaggi, un Focus Group individua possibili azioni da intraprendere: maggiore informazione, interventi di prevenzione e diagnosi precoce, formazione degli operatori sanitari, un modello Hub&Spoke sul territorio
Vaccinazione come strategia integrata nella prevenzione cardiovascolare, consensus ESC [Cardio]
Una dichiarazione di consenso della European Society of Cardiology (ESC), pubblicata sull’European Heart Journal, ha definito le vaccinazioni contro influenza, pneumococco e SARS-CoV-2 come interventi efficaci nella riduzione del rischio di eventi cardiovascolari, proponendole come quarto pilastro della prevenzione, accanto agli antipertensivi, ai farmaci ipolipemizzanti e ai trattamenti per il diabete.
First Blood Test for Alzheimer Biomarkers Receives FDA Clearance
This Medical News article discusses how the first FDA-cleared blood test for Alzheimer biomarkers should and shouldn’t be used.
Palliative Care Program for Community-Dwelling Individuals With Dementia
To the Editor The Indiana Palliative Excellence in Alzheimer Care Efforts (IN-PEACE) trial investigated the integration of palliative care within dementia care management for community-dwelling individuals with moderate to severe dementia and their caregivers. Although the trial reported a significant reduction in emergency department (ED) visits and hospitalizations, the lack of improvement in neuropsychiatric symptoms and caregiver distress raises important clinical questions.
Fda approva la sperimentazione della terapia genica sviluppata alla Maugeri per rara aritmia pediatrica [Fda]
La Food and Drug Administration (Fda) ha approvato la richiesta di IND (Investigational New Drug) presentata da Solid Biosciences Inc. (“Solid Bio”) per l’avvio della sperimentazione clinica della terapia genica denominata SGT-501 di Solid Bio per la Tachicardia Ventricolare Polimorfa Catecolaminergica (CPVT), una grave patologia aritmogena di origine genetica per la quale, ad oggi, non esistono trattamenti mirati.
Antibiotici in gravidanza: rischio malformativo associato al trimetoprim-sulfametossazolo nel primo trimestre [Infettivologia]
Le infezioni delle vie urinarie (IVU) rappresentano una delle complicanze infettive più frequenti durante la gravidanza, sia nella forma di batteriuria asintomatica che di cistite acuta. Entrambe le condizioni, se non trattate, possono favorire esiti avversi perinatali, ma il primo trimestre di gestazione è una fase estremamente delicata per lo sviluppo fetale, in cui l’esposizione a farmaci potenzialmente teratogeni può aumentare il rischio di malformazioni congenite. In questo contesto, l’uso di antibiotici deve bilanciare attentamente i benefici per la madre con i possibili rischi per il nascituro.
Alzheimer, a Milano si riunisce un'alleanza internazionale per affrontare la sfida comune #MindtheFuture [Neurologia e Psichiatria]
Quali strategie e politiche dovranno essere messe in atto a livello internazionale per affrontare quella che è stata definita una vera e propria pandemia del nuovo millennio? A queste e molte altre domande ha cercato di rispondere l’evento “MIND THE FUTURE – A CROSS COUNTRY ALZHEIMER READINESS PACT”, promosso dalla Fondazione della Sostenibilità Sociale, con il patrocinio della Società Italiana di Farmacologia e il supporto non condizionante di Lilly Italia, GE Healthcare, Biogen, Siemens e Fujirebio — che si è articolato in due giornate di lavoro che hanno preso avvio nella cornice istituzionale di Regione Lombardia e si sono concluse presso Università Vita Salute San Raffaele.
Una molecola potrebbe spiegare la riduzione della massa muscolare nel diabete di tipo 2
I ricercatori del Karolinska Institutet hanno identificato una molecola chiamata TMEM9B-AS1, un […]
A Città di Castello il 'Caffè Alzheimer' contro l'isolamento
Luogo d’incontro nel parco della residenza protetta ‘Muzi Betti’
Il CdA AIFA approva la rimborsabilità di 7 farmaci [Italia]
Un nuovo farmaco per la colite ulcerosa da moderata a grave e nuove indicazioni di farmaci per la sclerosi multipla e la fibrosi cistica. Sono alcuni dei trattamenti che saranno rimborsati dal Servizio sanitario nazionale (Ssn) a seguito delle decisioni assunte dal Consiglio di Amministrazione dell’Aifa nella seduta dell’8 luglio 2025.
In totale i farmaci interessati sono 7: 1 nuova molecola chimica, 1 medicinale generico e 5 farmaci già rimborsati per altre indicazioni.
Poetry, Memory, and Medicine
Poetry catalyzes memory, as other poems featured in JAMA have variously demonstrated. It is used directly among patients with dementia in programs such as the Alzheimer’s Poetry Project to reproducibly beneficial effect. “Missing Father” offers another example of the connections between poetry and memory. The poem both describes actual memories while at the same time seeming to spark more of them. The paradoxical double meaning of the title both reports on and grieves for the lost voice of the storyteller father—he is both absent and an actively yearned-for presence—while the first line’s immediacy of “this morning being” ironically unleashes vivid memories, from the sound of his voice “rising/from the worn pages” of a picture book to the uncanny word-picture of the speaker and her twin sister eagerly awaiting his return from work, “pajamas hanging on us/like wilted petunias.” The poem reanimates them all together as they chant the names of the book’s characters, simultaneously recalling both the tenderness of a distant childhood and enacting poetry’s mooted origins in the passing down of community wisdom through incantatory language. Yet even as poetry facilitates such recollection, and helps sustain the more practical, trying search for “nursing homes close and affordable,” ultimately it cannot bring back the long-gone, stricken father; instead, it becomes an act of healing, remembering that brighter time of more bearable loss, “a day when the only problem/was a carrot missing from/Mister McGregor’s garden.”
Memory Clinic Study Finds Lecanemab’s Adverse Events Manageable
Lecanemab became the first disease-modifying treatment for Alzheimer disease (AD) to receive traditional approval by the US Food and Drug Administration in 2023. Although the monoclonal antibody can remove amyloid-β plaques, the drug has been linked to brain changes known as amyloid-related imaging abnormalities (ARIA). A new study of patients with early symptomatic AD treated at an outpatient memory clinic suggests these and other adverse events are manageable in this population.
Investigating the eye in Down syndrome as a window to Alzheimers disease: the REVEAL protocol – a clinical cross-sectional study
Introduction
There is a need for early, non-invasive and inexpensive biomarkers for Alzheimer’s disease (AD), which could serve as a proxy measure in prevention and intervention trials that might eventually be suitable for mass screening. People with Down syndrome (DS) are the largest patient group whose condition is associated with a genetically determined increased risk of AD. The REVEAL study aims to examine changes in the structure and function of the eye in individuals with DS compared with those with mild cognitive impairment (MCI) and cognitively healthy control (HC) individuals. REVEAL will also explore whether these changes are connected to inflammatory markers previously associated with AD.
Methods and analysis
The protocol describes a cross-sectional, non-interventional, single-centre study recruiting three cohorts, including (1) participants with DS (target n=50; age range, 6–60 years), (2) participants with MCI (target n=50; age range, 50–80 years) and (3) HC participants (target n=50; age range, 50–80 years). The primary research objective is to profile retinal, choroidal and lenticular status using a variety of eye imaging modalities and retinal functional testing to determine potential associations with cognitive status. The REVEAL study will also measure and compare established blood markers for AD and proteomic and transcriptomic marker profiles between DS, MCI and HC groups. Between-group differences will be assessed with an independent sample t-test and 2 tests for normally distributed or binary measures, respectively. Multivariate regression analysis will be used to analyse parameters across all three cohorts. Data collection began in October 2023 and is expected to end in October 2025.
Ethics and dissemination
The study gained a favourable opinion from Health and Social Care Research Ethics Committee A (REC reference 22/NI/0158; approved on 2 December 2022; Amendment 22/0064 Amend 1, 5 April 2023; Amendment 22/0064 Amend 2; 23 May 2024; Amendment 22/0064 Amend 3; 25 June 2024; Amendment 22/0064 Amend 4; 16 January 2025; Amendment 22.0064 Amend 5; 9 May 2025; Amendment 22.0064 Amend 6; 9 June 2025). The study has also been reviewed and approved by the School of Biomedical Sciences Research Ethics Filter Committee within Ulster University. Findings from the REVEAL study will be presented to academic audiences at international conferences and peer-reviewed publications in targeted high-impact journals after data collection and analysis are complete. Dissemination activities will also include presentations at public events.
Strumento di intelligenza artificiale identifica i tipi di demenza
I ricercatori della Mayo Clinic hanno sviluppato un nuovo strumento […]
Improving Delirium Identification in Hospitalized Older Adults
Delirium affects one-third of hospitalized older adults and is associated with prolonged length of stay, institutional discharge, long-term functional and cognitive decline, Alzheimer disease and related dementias (AD/ADRD), and death. Moreover, the costs of delirium exceed $182 billion annually in the US alone. Despite these compelling data, accurate identification of delirium remains challenging, with more than half of delirium going unrecognized in routine care. While delirium prevention has advanced substantially, delirium treatment, which relies on early and accurate identification, lags. More than 40 tools are available for delirium assessment, ranging from short structured screens to in-depth reference standards. Evidence on how to implement these tools to improve delirium identification at the bedside, including which tool to use, who should administer it, how often, and how to educate and engage the care team, remains limited.